RxDoctor Payments DataLook up a doctor →

Peter Gulick, DO

Infectious Disease · Lansing, MINPI 1255383238

Payments from drug & device makers

$849,969in general payments, 2019–2025

Across 1,356 payments — averaging $626.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$415K
  • Gilead$228K
  • Merck$59K
  • GSK$50K
  • Janssen Products, LP$45K
  • AbbVie$43K
  • plus $10K from 18 others

What the payments were for

  • Consulting fees$37,9604%
  • Speaking & faculty fees$689,55581%
  • Travel & lodging$94,25811%
  • Food & beverage$27,7553%
  • Education$4420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$849,969 in reported general payments places this provider in the 95th percentile of 257 infectious disease providers in Michigan.

See all infectious disease providers in Michigan

Medicare billing

Part B allowed, 2024
$4,169
Medicare patients
20
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala259$1,039,525
DovatoDolutegravir Sodium/Lamivudine194$571,582
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf110$542,948
GenvoyaElviteg/Cob/Emtri/Tenof Alafen110$464,492
DescovyEmtricitabine/Tenofov Alafenam144$337,497
TivicayDolutegravir Sodium145$334,529
RukobiaFostemsavir Tromethamine36$308,544
TriumeqAbacavir/Dolutegravir/Lamivudi55$201,254
JulucaDolutegravir/Rilpivirine54$177,894
CabenuvaCabotegravir/Rilpivirine14$90,158
PifeltroDoravirine49$81,781
IsentressRaltegravir Potassium40$79,151
PrezcobixDarunavir/Cobicistat25$57,498
Darunavir32$35,066
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df11$4,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$228,251$1,841,513513 claims
Viiv Healthcare CompanyDovato, Tivicay, Rukobia, Triumeq, Juluca$415,455$1,683,961498 claims
Janssen Products, LPSymtuza$44,559$542,948110 claims
MerckPifeltro, Isentress$58,897$160,93289 claims
Johnson & JohnsonPrezcobix$894$57,49825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 257 infectious disease providers in Michigan.

Other infectious disease in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →